Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $15
Analysts Conflicted on These Healthcare Names: American Well (AMWL), Cogent Biosciences (COGT) and NeoGenomics (NEO)
Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth
Express News | Baird Maintains Neutral on Cogent Biosciences, Raises Price Target to $10
Cogent Biosciences, Inc. (COGT): This Small-Cap Healthcare Stock Is A Good Buy Right Now
A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $13 to $22
Positive Outlook for Cogent Biosciences Backed by Clinical Trial Progress and Efficient Management
Express News | Cogent Biosciences, Inc. : H.c. Wainwright Cuts Target Price to $17 From $19
Express News | Cogent Biosciences Inc: Peak Interim Futility Analysis Completed With No Changes to Study
Express News | Cogent Biosciences Inc: Top-Line Results Expected by End of 2025
Express News | Cogent Biosciences Announces Phase 3 Peak Trial in Patients With Gastrointestinal Stromal Tumors (Gist) Has Completed Enrollment and Advanced Past Interim Futility Analysis
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients With Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis
Hold Rating on Cogent Biosciences Amid Competitive Landscape and Anticipated Milestones
Cogent Biosciences Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on Cogent Biosciences, Lowers Price Target to $19
Cogent Biosciences Price Target Maintained With a $18.00/Share by Needham
Express News | 5Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target
Express News | Cogent Biosciences Inc : JP Morgan Cuts Target Price to $19 From $22
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16
Cogent Biosciences Garners Buy Rating Amid Promising Clinical Trials and Strategic Growth Potential